Ebola vaccine will be made available for emergency useBMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i386 (Published 22 January 2016) Cite this as: BMJ 2016;352:i386
- Anne Gulland
Some 300 000 doses of a vaccine against Ebola virus disease will be available from May for use in emergency situations and clinical trials, under a deal signed by the drug company Merck and by Gavi, a vaccine provider to the poorest countries in the world.
Gavi has signed an advance purchase agreement with Merck that gives the drug company $5m (£3.5m; €4.6m) to develop the rVSV-ZEBOV-GP live attenuated Ebola Zaire vaccine.
The agreement is based on the understanding that 300 000 doses of the vaccine will be available for clinical trials or emergency use by May this year and that …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial